CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (11,258)	$ (13,086)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	277	472
Gains on sales of fixed assets	(75)	(93)
Expenses for share-based compensation awards	749	2,609
Changes in assets and liabilities:
Decrease (increase) in accounts receivable	5,402	(887)
Decrease in other current assets	440	8
(Decrease) in accounts payable and accrued expenses	(630)	(2,232)
(Decrease) in deferred revenue - current	(460)	0
(Decrease) in deferred revenue - long term	0	(51)
Increase (decrease) in other liabilities	4	(534)
Net cash used in operating activities	(5,551)	(13,794)
Cash flows from investing activities:
Cash acquired in acquisition of subsidiary	1,888	0
Capital expenditures	(35)	(518)
Proceeds from sales of fixed assets	86	124
Proceeds from redemption of auction rate securities	100	100
Net cash provided by (used in) investing activities	2,039	(294)
Cash flows from financing activities:
Business Acquisition Issuance Costs	(45)	0
Proceeds from the exercise of stock options	3	82
Net cash (used in) provided by financing activities	(42)	82
Net decrease in cash and cash equivalents	(3,554)	(14,006)
Cash and cash equivalents at beginning of period	58,838	70,105
Cash and cash equivalents at end of period	55,284	56,099
Supplemental Cash Flow Elements [Abstract]
Acquisition-related contingent consideration liability	15,900	0
Progenics common stock consideration	$ 11,265	$ 0